Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens

Shortridge, Dee; Arends, S J Ryan; Streit, Jennifer M; Castanheira, Mariana

doi:10.1128/aac.01264-21

Cited by 5 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is limited international data about the use of colistin S. maltophilia infections. Even though minocycline and tigecycline have low minimal inhibitory concentrations among S. maltophilia isolates [ 34 , 35 , 42 ] and some studies have shown clinical outcomes comparable to TMP-SMX [ 43 ], 65% of the isolates in our study had a tigecycline MIC of ≥ 4 μg/ml. They were considered non-susceptible using interpretive criteria for Enterobacteriaceae [ 9 , 44 ].…”

Section: Discussionmentioning

confidence: 64%

Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study

Nair¹,

Sasi²,

Maslamani³

et al. 2022

Cureus

View full text Add to dashboard Cite

Background Stenotrophomonas maltophilia is a rapidly emerging nosocomial pathogen with intrinsic or acquired resistance mechanisms to several antibiotic classes. It can cause life-threatening opportunistic pneumonia, particularly among hospitalized patients. Incidence of infections by S. maltophilia has been reported as 0.07-0.4% of hospital discharges, but its mortality is 20 -60%. This is the first study from Qatar indexing the clinical and epidemiological characteristics and antibiotic susceptibility of S. maltophilia. Materials and methods This retrospective descriptive epidemiological study was conducted in 6 tertiary care hospitals under Hamad Medical Corporation in Doha, Qatar, analyzing inpatient respiratory isolates of S. maltophilia during 2016-17. Out-patients, children below 14 years, and non-respiratory samples except blood cultures in patients with pneumonia were excluded. Clinical records were reviewed to identify possible risk factors. Infection and colonization were identified using the Centers for Disease Control and Prevention (CDC) algorithm for clinically defined pneumonia and statistically analyzed using the chi-square test and Pearson's correlation. Results S. maltophilia was isolated from 2.07% (317/15312) of all respiratory samples received in the microbiology lab during our study period. Three hundred seventeen patients studied had a mean age of 60 ± 20 years, and 68% were men. Most of the isolates were from sputum (179), followed by tracheal aspirate (82) and bronchoscopy (42). Fourteen blood culture samples from patients diagnosed with pneumonia were also included. 67% were hospitalized for more than two weeks, 39.1% were on mechanical ventilators, and 88% had received a broad-spectrum antibiotic before the event. 29.1% were deemed to have an infection and 70.9% colonization. Incidence of infection in those with Charlson’s Co-morbidity Index (CCI) ≥ 3 was 36.5% compared to 24.2% in those with CCI < 3 (Relative Risk (RR)=1.52; 95% CI: 1.04,2.18; p=0.01). Patients with recent chemotherapy, immunosuppressant, or steroid use had a significantly higher infection risk than those without (69.2% v/s 23.3% RR=2.96; 95% CI:2.2,3.9; p<0.005). The most common symptoms in patients with infection were fever (96%) and expectoration (61.9%). The most common radiological finding was lobar consolidation (71.6%). Mean CRP and procalcitonin were 106.5±15.5 mg/l and 12.3 ± 14 ng/ml. Overall mortality was 16.3%. Patients on mechanical ventilator with IBMP-10 score ≥ 2 had 22.8% mortality compared to 5.7% in those with score < 2 (RR=3.9;95%CI:0.9,16.6; p<0.015). As per The US Clinical and Laboratory Standards Institute (CSLI) breakpoint values, Trimethoprim-Sulfamethoxazole (TMP-SMX) showed the highest sensitivity (97.8%), followed by levofloxacin (71.6%). 0.3% of samples were pan-drug resistant. Conclusions S. maltophilia is a f...

show abstract

Section: Discussionmentioning

confidence: 64%

Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study

Nair¹,

Sasi²,

Maslamani³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Due to its toxicity, chloramphenicol is rarely used. We tested tigecycline, a derivative of minocycline, which appears to demonstrate a good activity against Achromobacter (MIC 50 = 0.5 mg/L and 1 mg/L for tigecycline and minocycline, respectively) [33,34]. Overall, clinical studies are needed to make recommendations for the treatment of Achromobacter, and more generally of non-fermenters, especially considering the increase in their prevalence and the recent availability of new antimicrobial agents.…”

Section: Discussionmentioning

confidence: 99%

“…As Achromobacter, other non-fermenting Gram-negative bacilli, such as Stenotrophomonas maltophilia, Burkholderia cepacia complex, Pandoraea or Cupriavidus are increasingly isolated from the respiratory tract of PWCF and are characterised by their high resistance to antibiotics. For all these bacteria, SXT and tetracycline (minocycline) are among the most active antimicrobial agents [8,22,[34][35][36][37][38]. For most of them, carbapenems represent one of the most active antimicrobial agents except for S. maltophilia, which is intrinsically resistant due to a chromosomal carbapenemase.…”

Section: Discussionmentioning

confidence: 99%

In Vitro Activity of 22 Antibiotics against Achromobacter Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options?

Lamoureux

Mashi

Ramel³

et al. 2021

Microorganisms

View full text Add to dashboard Cite

Bacteria belonging to the genus Achromobacter are increasingly isolated from respiratory samples of people with cystic fibrosis (PWCF). The management of this multidrug-resistant genus is challenging and characterised by a lack of international recommendations, therapeutic guidelines and data concerning antibiotic susceptibility, especially concerning the newer antibiotics. The objective of this study was to describe the antibiotic susceptibility of Achromobacter isolates from PWCF, including susceptibility to new antibiotics. The minimum inhibitory concentrations (MICs) of 22 antibiotics were determined for a panel of 23 Achromobacter isolates from 19 respiratory samples of PWCF. Two microdilution MIC plates were used: EUMDROXF® plate (Sensititre) and Micronaut-S Pseudomonas MIC® plate (Merlin) and completed by a third method if necessary (E-test® or UMIC®). Among usual antimicrobial agents, the most active was imipenem (70% susceptibility). Trimethoprim-sulfamethoxazole, piperacillin and tigecycline (65%, 56% and 52% susceptibility, respectively) were still useful for the treatment of Achromobacter infections. Among new therapeutic options, β-lactams combined with a β-lactamase-inhibitor did not bring benefits compared to β-lactam alone. On the other hand, cefiderocol appeared as a promising therapeutic alternative for managing Achromobacter infections in PWCF. This study provides the first results on the susceptibility of clinical Achromobacter isolates concerning new antibiotics. More microbiological and clinical data are required to establish the optimal treatment of Achromobacter infections.

show abstract

Minocycline mitigates Aβ and TAU pathology, neuronal dysfunction, and death in the PSEN1 E280A cholinergic-like neurons model of familial Alzheimer’s disease

Giraldo-Berrio,

Jimenez-Del-Rio,

Velez-Pardo

2024

Neuropharmacology

View full text Add to dashboard Cite

Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens

Cited by 5 publications

References 27 publications

Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study

Clinical and Epidemiological Characteristics of Stenotrophomonas maltophilia Associated Lower Respiratory Tract Infections in Qatar: A Retrospective Study

In Vitro Activity of 22 Antibiotics against Achromobacter Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options?

Minocycline mitigates Aβ and TAU pathology, neuronal dysfunction, and death in the PSEN1 E280A cholinergic-like neurons model of familial Alzheimer’s disease

Contact Info

Product

Resources

About